Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer

Bookmark and Share
Published: 27 Jul 2020
Views: 840
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA

Dr Grace Martin speaks about the use of the PARP inhibitors for the treatment of prostate cancer from her perspective as an oncology pharmacist, stemming from her work on the use of olaparib for the treatment of metastatic castration-resistant prostate cancer.

Dr Martin provides a background on the use of PARP inhibitors in prostate cancer, explaining why there is a need to find a targeted treatment for these patients. She discusses some of the existing research in this area and reports on recent FDA approvals of PARP inhibitors for the treatment of prostate cancer.

Dr Martin describes her own clinical experience of using PARP inhibitors to treat patients with prostate cancer. She concludes by commenting on how she can see the use of these drugs developing in the near future.

This programme has been supported by an unrestricted educational grant from Pfizer.